Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Liver Failure Complicated by Multi-System Invasive Fungal Infections

The Gut Microbiome and Intestinal Failure-Associated Liver Disease

[Research Advances in Diagnosis and Treatment of Liver Failure in 2016].

Importance Of Fibrosis 4 Index Score And Mode Of Anti-Fungal Treatment To The Outcome Of Cryptococcal Meningitis In Hepatitis B Virus-Infected Patients

Invasive fungal infections in liver transplantation.

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Clinical characteristic analysis for invasive fungal infection in neonatal intensive care unit

Clinical Characteristics of Liver Failure Complicated by Candida Infection

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Progress on Diagnosis and Treatment of Refractoryascites in Patients with Hepatic Failure

Microbial Infections As A Trigger For Acute-Onchronic Liver Failure: A Review

Impact of Invasive Fungal Infection on Outcomes of Severe Sepsis: a Multicenter Matched Cohort Study in Critically Ill Surgical Patients

Clinical characteristics of liver failure complicated with aspergillus infection

Research progress on the role of probiotics in acute liver failure

Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure.

Diagnosis and Treatment of Fungal Infection after Orthotopic Liver Transplantation

Analysis of Correlative Factors in Infection of Liver Transplant Recipients.

Efficacy and Safety of Caspofungin Followed by Itraconazole Oral Solution for Patients with Invasive Fungal Infection

Emerging Invasive Fungal Infections: Clinical Features and Controversies in Diagnosis and Treatment Processes

Invasive Fungal Infections in Acute Decompensation of Cirrhosis: Epidemiology, Predictors of 28-Day Mortality, and Outcomes

Comparison of fungal vs bacterial infections in the medical intensive liver unit: Cause or corollary for high mortality?